EQL Pharma AB (publ) (STO:EQL)

EQL Pharma AB Statistics

Total Valuation

EQL Pharma AB has a market cap or net worth of SEK 772.20 million. The enterprise value is 1.13 billion.

Market Cap	772.20M
Enterprise Value	1.13B

Important Dates

The last earnings date was Friday, May 8, 2026.

Earnings Date	May 8, 2026
Ex-Dividend Date	n/a

Share Statistics

EQL Pharma AB has 29.53 million shares outstanding. The number of shares has increased by 0.92% in one year.

Current Share Class	29.53M
Shares Outstanding	29.53M
Shares Change (YoY)	+0.92%
Shares Change (QoQ)	+0.73%
Owned by Insiders (%)	2.38%
Owned by Institutions (%)	1.59%
Float	21.72M

Valuation Ratios

The trailing PE ratio is 62.26 and the forward PE ratio is 32.17.

PE Ratio	62.26
Forward PE	32.17
PS Ratio	1.78
PB Ratio	2.89
P/TBV Ratio	n/a
P/FCF Ratio	33.70
P/OCF Ratio	27.23
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 16.21, with an EV/FCF ratio of 49.48.

EV / Earnings	90.43
EV / Sales	2.62
EV / EBITDA	16.21
EV / EBIT	23.29
EV / FCF	49.48

Financial Position

The company has a current ratio of 1.92, with a Debt / Equity ratio of 1.68.

Current Ratio	1.92
Quick Ratio	0.97
Debt / Equity	1.68
Debt / EBITDA	6.41
Debt / FCF	19.57
Interest Coverage	1.60

Financial Efficiency

Return on equity (ROE) is 5.14% and return on invested capital (ROIC) is 5.31%.

Return on Equity (ROE)	5.14%
Return on Assets (ROA)	3.67%
Return on Invested Capital (ROIC)	5.31%
Return on Capital Employed (ROCE)	7.60%
Weighted Average Cost of Capital (WACC)	5.71%
Revenue Per Employee	7.87M
Profits Per Employee	227,964
Employee Count	55
Asset Turnover	0.52
Inventory Turnover	1.42

Taxes

In the past 12 months, EQL Pharma AB has paid 5.67 million in taxes.

Income Tax	5.67M
Effective Tax Rate	31.13%

Stock Price Statistics

The stock price has decreased by -69.59% in the last 52 weeks. The beta is 0.37, so EQL Pharma AB's price volatility has been lower than the market average.

Beta (5Y)	0.37
52-Week Price Change	-69.59%
50-Day Moving Average	46.54
200-Day Moving Average	59.39
Relative Strength Index (RSI)	25.19
Average Volume (20 Days)	146,671

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, EQL Pharma AB had revenue of SEK 432.66 million and earned 12.54 million in profits. Earnings per share was 0.42.

Revenue	432.66M
Gross Profit	162.84M
Operating Income	48.69M
Pretax Income	18.21M
Net Income	12.54M
EBITDA	69.96M
EBIT	48.69M
Earnings Per Share (EPS)	0.42

Balance Sheet

The company has 86.76 million in cash and 448.40 million in debt, with a net cash position of -361.64 million or -12.25 per share.

Cash & Cash Equivalents	86.76M
Total Debt	448.40M
Net Cash	-361.64M
Net Cash Per Share	-12.25
Equity (Book Value)	267.06M
Book Value Per Share	9.04
Working Capital	193.64M

Cash Flow

In the last 12 months, operating cash flow was 28.36 million and capital expenditures -5.44 million, giving a free cash flow of 22.92 million.

Operating Cash Flow	28.36M
Capital Expenditures	-5.44M
Depreciation & Amortization	21.27M
Net Borrowing	9.76M
Free Cash Flow	22.92M
FCF Per Share	0.78

Margins

Gross margin is 37.64%, with operating and profit margins of 11.25% and 2.90%.

Gross Margin	37.64%
Operating Margin	11.25%
Pretax Margin	4.21%
Profit Margin	2.90%
EBITDA Margin	16.17%
EBIT Margin	11.25%
FCF Margin	5.30%

Dividends & Yields

EQL Pharma AB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.92%
Shareholder Yield	-0.92%
Earnings Yield	1.62%
FCF Yield	2.97%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	5